Form 4: Cardio Diagnostics Director Peter Fung Reports Future Stock Option Acquisition Under 10b5-1 Plan

Cardio Diagnostics Holdings, Inc. Director Peter K Fung reported a planned acquisition of 1,736 stock options at an exercise price of $3.6 per share, effective June 30, 2025, under a Rule 10b5-1 plan.

Summary

• Peter K Fung, a Director of Cardio Diagnostics Holdings, Inc. (CDIO), is set to acquire 1,736 stock options.
• The acquisition is planned under a Rule 10b5-1 contract, instruction, or written plan.
• The effective date of this acquisition, and the date the options become exercisable, is June 30, 2025.
• The stock options have an exercise price of $3.6 per share.
• The options are scheduled to expire on June 30, 2035.
• Following this planned acquisition, Peter Fung will beneficially own a total of 2,443 derivative securities, specifically stock options.

Sentiment

Score: 6

Explanation: The acquisition of stock options by a director is generally a neutral to slightly positive signal, as it aligns the director's interests with shareholder value. It is a compensation event rather than an operational achievement, hence not a strong positive.

Positives

• The acquisition of stock options by a director aligns their financial interests with those of shareholders, as the options gain value if the company's stock price increases above the exercise price.
• The options have a long expiration date of June 30, 2035, providing a significant window for potential exercise and value realization.

Negatives

• No direct negatives are apparent from an option grant itself; the value is contingent on future stock performance.

Risks

• The value of the stock options is entirely dependent on the future performance of Cardio Diagnostics Holdings, Inc.'s common stock. If the stock price does not rise above the exercise price of $3.6, the options may expire worthless.
• Equity compensation, while aligning interests, can dilute existing shareholder value if options are exercised and new shares are issued.

Future Outlook

This Form 4 reports a planned insider transaction and does not contain forward-looking statements or guidance regarding the company's operational or financial performance.

Industry Context

This is an insider transaction report, which is a standard disclosure for publicly traded companies. The grant of stock options is a common form of equity compensation for directors across various industries, including healthcare and diagnostics, designed to align management incentives with shareholder value.

Comparison to Industry Standards

• The grant of stock options to a director is a common practice in publicly traded companies as a form of equity compensation.
• The use of a Rule 10b5-1 plan for such transactions is standard practice to provide an affirmative defense against insider trading allegations, demonstrating that the transaction was pre-planned and not based on material non-public information.

Related Party Transactions

• The acquisition of stock options by a director is a common form of related-party compensation.

Stakeholder Impact

• Shareholders: The planned option grant aligns the director's financial interests with those of shareholders, as the options gain value if the stock price increases.

Key Dates

Keywords

Cardio Diagnostics Holdings Inc., CDIO, Peter K Fung, Form 4, SEC filing, stock options, insider transaction, beneficial ownership, director compensation, equity compensation, Rule 10b5-1 plan